Company Profile
Unicycive Therapeutics Stock Price, News & Analysis
- Ticker:
- UNCY
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.05 USD (-3.44%)
Close
Last updated: August 6, 2026
193M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, UNCY closed down 3.44% at $5.05. No new same-company headline was identified in the current news window.
Company overview
Kidney Disease Therapeutics
Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.
Oxylanthanum Carbonate
Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients, designed to reduce pill burden relative to existing therapies.
Commercial Preparation
Unicycive is preparing market access, manufacturing, and launch capabilities while the resubmitted NDA is under review.
Future catalysts
The FDA PDUFA action date for the oxylanthanum carbonate NDA is June 29, 2026.
Recent news
- 01
- 02
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Source: Unicycive Therapeutics
- 03
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Source: Unicycive Therapeutics
- 04
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Source: Unicycive Therapeutics
- 05
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
Source: Unicycive Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Unicycive Therapeutics (UNCY)?
Unicycive Therapeutics (UNCY) most recently closed at 5.05 USD, a -3.44% move versus the previous session.
What is the market cap of Unicycive Therapeutics (UNCY)?
Unicycive Therapeutics currently has a market capitalization of 193M USD on BioPharmSignal.
What does Unicycive Therapeutics do?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease. Oxylanthanum Carbonate Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients, designed to reduce pill burden relative to existing therapies. Commercial Preparation Unicycive is preparing market...
On which exchange is UNCY stock listed?
Unicycive Therapeutics (UNCY) is associated with NASDAQ, United States, Biopharma.
What is Kidney?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.
Which conditions is Unicycive Therapeutics targeting with Kidney?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease. Oxylanthanum Carbonate Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients, designed to reduce pill burden relative to existing therapies. Commercial Preparation Unicycive is preparing market...
How does Unicycive Therapeutics describe recent progress with Kidney?
The FDA PDUFA action date for the oxylanthanum carbonate NDA is June 29, 2026.
What is Disease?
Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease.